In another guideline established in Australia, refractory MIS-C can be managed by increasing the dose of glucocorticoids, using a second dose of high-dose IVIg, or by adding biological immunomodulators, such as anti-IL-1, anti-IL-6, or anti-TNF agents [6]. The gene discussed is IL6; the disease is COVID-19–associated multisystem inflammatory syndrome in children.